Clinical Trials Logo

Clinical Trial Summary

To determine whether 3-month versus 6-month professional CGM utilization improves time spent in target range of 70-140mg/dl in patients with poorly controlled T2DM not treated with insulin.


Clinical Trial Description

Patients not receiving any insulin treatment with an HbA1c ≥ 7.5% before their scheduled primary care appointment will be invited to participate in the study and wear professional CGM for at least 3 days at either 3 intervals (baseline, 3-month and 6-month) or 2 intervals (baseline and 6-month). After removal, the downloaded report will provide quantitative data to determine the percent of time spent in the target range. The 6-month data will be analyzed to determine if frequency of professional CGM wear positively affects time spent in target range. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03067480
Study type Interventional
Source East Tennessee State University
Contact
Status Terminated
Phase N/A
Start date June 6, 2017
Completion date September 30, 2019

See also
  Status Clinical Trial Phase
Completed NCT01373814 - Nutritional Therapy for Diabetic Cardiomyopathy
Recruiting NCT05469659 - Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD) Phase 2
Completed NCT05376930 - Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM. Phase 3
Recruiting NCT04682795 - Comparison of Safety and Efficacy of Needle-Free Injector and Insulin Pen in Patients With T2DM N/A
Recruiting NCT06350890 - Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Phase 3
Completed NCT04634500 - The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes. Phase 3
Recruiting NCT03789695 - RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD Phase 4
Completed NCT04632862 - The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus. Phase 3
Completed NCT04688359 - Effectiveness of Nurse-coordinated Follow-up Program in Primary Care for People at Risk for T2DM N/A
Completed NCT05983289 - Single Escalating Dose Study Of HSK7653 In Healthy Subjects Phase 1
Recruiting NCT04272359 - Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus
Completed NCT03467932 - A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus Phase 2
Completed NCT05376969 - Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin Phase 3
Recruiting NCT06415773 - Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Phase 3
Recruiting NCT06094491 - Virtual Diabetes Group Visits Across Health Systems Phase 2
Completed NCT05279911 - Effect of Low-level Laser Therapy on Type II Controlled Diabetic Patients After Dental Implant Insertion N/A
Active, not recruiting NCT03257449 - Effect of Viscous Soluble Fibres on Body Weight N/A
Terminated NCT04754334 - A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus Phase 3
Not yet recruiting NCT06293417 - To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM
Not yet recruiting NCT03658031 - Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction Phase 3